All In Biotech

Drug Trial Radar · NCT06934226

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 752 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

752

Actual

Start

Apr 15, 2025

Primary completion

Nov 17, 2025

Study completion Aug 20, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • JNJ-77242113Drug

    JNJ-77242113 will be administered orally.

  • Matching Placebo to JNJ-77242113Drug

    Matching placebo will be administered orally.

  • UstekinumabDrug

    Ustekinumab will be administered subcutaneously.

  • Matching Placebo to UstekinumabDrug

    Matching placebo will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16Time frame: Week 16
  2. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16Time frame: Week 16

Locations

160 sites in 13 countries. Site status is shown where the registry gives one.

  • Cahaba Research Inc

    Birmingham, Alabama

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • T Joseph Raoof Md Inc

    Encino, California

  • First OC Dermatology

    Fountain Valley, California

  • Dermatologist Medical Group of North County, Inc.

    Oceanside, California

  • NorCal Clinical Research

    Rocklin, California

  • Integrative Skin Science and Research

    Sacramento, California

  • MedDerm Associates

    San Diego, California

  • Southern California Dermatology

    Santa Ana, California

  • Olive View-UCLA Education & Research Institute

    Sylmar, California

  • University of Conn Health Center

    Farmington, Connecticut

  • Driven Research LLC

    Miami, Florida

  • Bioclinical Research Alliance Inc.

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Forcare Clinical Research Inc

    Tampa, Florida

  • Hamilton Research LLC

    Alpharetta, Georgia

  • Northshore Medical Group

    Skokie, Illinois

  • Indiana Clinical Trial Center

    Plainfield, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Equity Medical

    Bowling Green, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Metro Boston Clinical Partners

    Brighton, Massachusetts

  • The Derm Institute of West Michigan

    Caledonia, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • Cleaver Dermatology

    Kirksville, Missouri

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Mount Sinai Doctors Dermatology

    New York, New York

  • Sadick Research Group

    New York, New York

  • Wilmington Dermatology Center

    Wilmington, North Carolina

  • Optima Research

    Boardman, Ohio

  • Apex Dermatology Mayfield Heights

    Mayfield Heights, Ohio

  • Oregon Medical Research Center

    Portland, Oregon

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Clinical Research Philadelphia

    Philadelphia, Pennsylvania

  • UPMC Department of Dermatology

    Pittsburgh, Pennsylvania

  • Health Concepts

    Rapid City, South Dakota

  • Advanced Research Experts PLLC

    Nashville, Tennessee

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.